Hendrik‐Tobias Arkenau

Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial

Kohei Shitara, Toshihiko Doi, Mikhail Dvorkin et al. · The Lancet Oncology · 2018 · 495 citations

Gastrointestinal Oncology, Trifluridine/tipiracil Versus Placebo, Medicine +9

Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial

Roy S. Herbst, Hendrik‐Tobias Arkenau, Rafael Santana-Dávila et al. · The Lancet Oncology · 2019 · 271 citations · Full text

Urothelial Carcinomas, Medicine, Clinical Trials +9

First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors

Gerald S. Falchook, Jeffrey R. Infante, Hendrik‐Tobias Arkenau et al. · EClinicalMedicine · 2021 · 250 citations · Full text

Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience

David Olmos, Hendrik‐Tobias Arkenau, Joo Ern Ang et al. · Annals of Oncology · 2008 · 247 citations · Full text

Urology, Genitourinary Cancer, Medicine +8

Futibatinib, an Irreversible FGFR1–4 Inhibitor, in Patients with Advanced Solid Tumors Harboring <i>FGF</i> / <i>FGFR</i> Aberrations: A Phase I Dose-Expansion Study

Funda Meric‐Bernstam, Rastislav Bahleda, Cinta Hierro et al. · Cancer Discovery · 2021 · 239 citations · Full text